Aapro, M., Hadji, P., Santini, D. et al. (2 more authors) (2025) Biosimilars in osteoporosis treatment: focus on denosumab. Expert Opinion on Biological Therapy. ISSN: 1471-2598
Abstract
Osteoporosis is a significant public health issue due to its associated morbidity, mortality, and economic burden. Despite available effective treatments, a treatment gap persists, characterized by delayed diagnosis, undertreatment, and poor adherence. Biosimilars, such as biosimilars for denosumab, offer an opportunity to improve treatment accessibility and affordability for osteoporosis and cancer-related bone loss. This review explores the current treatment challenges in osteoporosis, the potential of denosumab biosimilars in improving access and outcomes, and the necessity of a multidisciplinary, patient-centered approach. The emergence of biosimilars for denosumab offers an opportunity to enhance accessibility and affordability of osteoporosis treatment, as biosimilars provide effective and economic versions of reference biologic therapies. A multidisciplinary approach is vital in managing osteoporosis, central to which is the patient, whose preferences, values, and lifestyle must guide the treatment plan. Healthcare providers play a crucial role in educating patients, promoting adherence to prescribed treatments, and involving patients in their own care to improve health outcomes.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2025 The Authors. Except as otherwise noted, this author-accepted version of a journal article published in Expert Opinion on Biological Therapy is made available via the University of Sheffield Research Publications and Copyright Policy under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ |
Keywords: | Biosimilar; bone loss; denosumab; multidisciplinary; osteoporosis; patient education; undertreatment |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine and Population Health |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 31 Jul 2025 14:40 |
Last Modified: | 01 Aug 2025 14:02 |
Status: | Published online |
Publisher: | Taylor and Francis Group |
Refereed: | Yes |
Identification Number: | 10.1080/14712598.2025.2540471 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:229927 |
Download
Filename: 250724_Sandoz_Expert_review_Bone_Health_resubmission.pdf
Licence: CC-BY 4.0